Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 0 · 0%High 0 · 0%

Risk of acute mountain sickness · participants at risk of high altitude illness

Acetazolamide may leads to lower risk of acute mountain sickness compared with spironolactone (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
RR 0.36 [0.18, 0.7]
1 study · 232 participants
Low

Risk of high altitude pulmonary oedema · participants at risk of high altitude illness

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
Low

Risk of high altitude cerebral oedema · participants at risk of high altitude illness

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
Low

Risk of adverse events ‐ not reported · participants at risk of high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found